Four cases, one fatal, of rare clots with low blood platelets were reported among those vaccinated with the Johnson & Johnson shot which has prompted the EU drug regulator to review the vaccine.
The EMA has already approved the Johnson & Johnson vaccine for use, but its rollout across the 27-nation EU is not due to start until later this month.
European Medicines Agency has also widened the probe on the AstraZenca jab after five cases reported a blood vessel leak which caused swelling and a drop in blood pressure after vaccination in recipients.